LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, ...

LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

On Friday, Neumora Therapeutics Inc (NMRA) stock saw a decline, ending the day at $16.49 which represents a decrease of $-0.47 or -2.77% from the prior close of $16.96. The stock opened at $17 and ...

Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.

FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a ...

Leerink Partnrs lifted their FY2028 EPS estimates for LENZ Therapeutics in a research report issued on Tuesday, October 15th.

The large Bridge Closed signs at a Lester Avenue construction site in Johnson City aren't deterring some people from trying ...

In terms of valuation, Neumora Therapeutics Inc’s market capitalization stands at $2.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today ...